Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 6.6% – Here’s What Happened

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price dropped 6.6% during trading on Thursday . The company traded as low as $23.24 and last traded at $22.93. Approximately 44,313 shares were traded during trading, a decline of 68% from the average daily volume of 139,864 shares. The stock had previously closed at $24.56.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Stock Performance

The company’s 50-day moving average price is $18.82 and its 200 day moving average price is $17.89.

Insider Buying and Selling

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert W. Duggan acquired 55,256 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was acquired at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the acquisition, the director now directly owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 71.50% of the stock is owned by corporate insiders.

Institutional Trading of Pulse Biosciences

Several large investors have recently made changes to their positions in PLSE. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pulse Biosciences during the third quarter worth $588,000. Charles Schwab Investment Management Inc. boosted its holdings in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares in the last quarter. State Street Corp boosted its holdings in Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after buying an additional 69,696 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after buying an additional 33,200 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new stake in Pulse Biosciences during the third quarter worth $378,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.